Cancers linked to the human papillomavirus (HPV) rose dramatically in a 15-year period, even as the rates of young people being vaccinated climbed, the Centers for Disease Control and Prevention (CDC) reported. The 43,371 new cases of HPV-associated cancers reported nationwide in 2015 marked a 44 percent jump from the 30,115 cases reported in 1999, according to a CDC analysis. HPV vaccination rates have improved over the years, but not fast enough to stem the rise in cancers, the CDC said. Oropharyngeal (throat) cancer was the most common HPV-associated cancer in 2015; accounting for 15,479 cases among males and 3,438 among females, the CDC data show. HPV infects about 14 million people each year and between 1999 and 2015 rates of oropharyngeal (throat) and vulvar cancer increased, vaginal and cervical cancer rates declined, and penile cancer rates were stable, according to the CDC.
When 9-year-old Jeremy Brown is in pain, it feels like he is being stabbed, while the pain experienced by Deborah Oliver, 40, is like a hundred simultaneous charley horses. Brown, of Bridgeport, and Oliver, of New Haven, have sickle cell disease (SCD), a genetic blood disorder that causes excruciating pain, life-threatening complications and a shortened life expectancy. Almost one-half of sickle cell patients die in their 40s. The disease affects some 100,000 Americans, about one in 365 African Americans and one out of 16,300 Hispanics; and in lesser numbers, people with Middle Eastern, Indian, Caribbean and Mediterranean ancestries. An estimated 2,000 people in Connecticut have SCD.
Edith Baker of Plainville faced a devastating reality that patients with advanced cancer inevitably confront. She had stopped responding to conventional treatment. Radiation and chemotherapy could no longer contain her stage 4 bladder cancer. But there was a ray of hope. Baker’s oncologist at Saint Francis Hospital and Medical Center referred her to a clinical trial at UConn Health involving two immunotherapy drugs: the FDA-approved Keytruda (pembrolizumab) from Merck & Co., credited with successfully treating former President Jimmy Carter’s melanoma; and Epacadostat (IDO1 inhibitor), an experimental drug from Incyte Corp.
The state Medical Examining Board Tuesday disciplined a Fairfield pulmonologist for improperly prescribing opioids and a former UConn Health doctor who had stolen medication from the health center for his private practice. Dr. Igal Staw, who works at Respiratory Associates in Fairfield, was reprimanded, fined $7,500 and has been permanently restricted from prescribing opioids, under a consent order he agreed to. He also must hire a supervisor to monitor his drug prescriptions and will be placed on two years of probation if his state registration to prescribe controlled substances is ever reinstated, the order said. In 2012 and 2013, Staw prescribed opioids to eight patients with chronic pain, including some who may have been abusing the medicine, the order said. He also failed to document the reasons for the prescriptions or justify in the patients’ medical charts why he was increasing the doses, state records show.
Penalties levied against Connecticut companies for violations of occupational safety rules dropped by more than half between 2011 and 2015, and the number of cases with penalties fell by 40 percent in the same time period, according to a C-HIT analysis of federal Occupational Safety & Health Administration (OSHA) data. Data from the agency’s offices in Bridgeport and Hartford show initial penalties against Connecticut employers totaled $10.86 million in 2011 and dropped to $5.07 million in 2015. Companies were able to negotiate settlements, lowering penalty payments to $6.26 million in 2011, and $3.51 million in 2015. For the first nine months of 2016, the downward trends in cases and fines are continuing, the data show. Reasons for the declines vary: Government officials point to safer workplaces and more compliance with regulations.
Dozens of Connecticut doctors accepted six-figure payments from drug and medical device manufacturers in 2015 for consulting, speaking, meals and travel, with six of the 10 highest-paid physicians affiliated with academic institutions, new federal data show. The top 10 doctors – less than 0.1 percent of the 11,000 who received payments – took in $3.6 million, or nearly 15 percent of the total $24.9 million paid out. Among them is the dean of the Yale School of Medicine, Dr. Robert Alpern, who received $445,398 in 2015 from two companies – Abbott Laboratories and AbbVie – in consulting fees, meals and travel expenses for serving on the boards of both companies. In 2014, he received $458,194 from the two companies. The Yale medical school began a research partnership with AbbVie in 2013, after the pharmaceutical company spun off from Abbott Laboratories.